Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,755.20
(
-1.56%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
107.79
(
1.13%
)
Bitcoin
71,091.34
(
-0.21%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 157806

Thursday, 01/16/2014 4:33:57 PM

Thursday, January 16, 2014 4:33:57 PM

Post# of 257257
FDA advisory panel votes 10-0 against Xarelto for secondary prevention of MACE (i.e. prevention following a recent MI):

http://in.reuters.com/article/2014/01/16/us-johsonjohnson-idINBREA0F1OY20140116

The panelists did not find the data from a single trial convincing, especially when considering that some data points were missing.

The panel’s decision has no effect on Xarelto’s approved FDA indications for AF/stroke prevention and VTE treatment/prevention.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now